Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Gross Profit (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Gross Profit for 4 consecutive years, with $30.9 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 15728.72% to $30.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.3 million through Dec 2025, up 1267.79% year-over-year, with the annual reading at $33.3 million for FY2025, 1267.79% up from the prior year.
  • Gross Profit for Q4 2025 was $30.9 million at Orchestra BioMed Holdings, up from $812000.0 in the prior quarter.
  • The five-year high for Gross Profit was $30.9 million in Q4 2025, with the low at $195000.0 in Q4 2024.
  • Average Gross Profit over 4 years is $2.6 million, with a median of $818000.0 recorded in 2022.
  • The sharpest move saw Gross Profit plummeted 79.52% in 2023, then skyrocketed 15728.72% in 2025.
  • Over 4 years, Gross Profit stood at $1.0 million in 2022, then plummeted by 79.52% to $215000.0 in 2023, then decreased by 9.3% to $195000.0 in 2024, then surged by 15728.72% to $30.9 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $30.9 million, $812000.0, and $790000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.